Abstract
A retrospective chart review was conducted on 11 patients with a remote history of acquired brain injury (ABI) referred for psychiatric treatment who were treated with divalproex sodium alone or in combination with other psychotropic medications. The patients were highly heterogeneous. They had a variety of psychiatric symptoms and frequently received concomitant psychotropic medications. The mean daily dose of divalproex was 1,818+/-791 mg/day, serum valproic acid level 85.6+/-29.6 microg/ml. Mean Clinical Global Impression improvement score was 1.9+/-0.5. This is the largest postacute case series reported. It demonstrates that divalproex sodium is well tolerated and effective in reducing a broad range of neurobehavioral symptoms in psychiatric patients with a remote history of ABI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Neuropsychiatry and Clinical Neurosciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
